Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
TOLEROGENIC SYNTHETIC NANOCARRIER THAT LOWERS CYTOTOXIC T LYMPHOCYTE RESPONSE
Document Type and Number:
Japanese Patent JP2021183612
Kind Code:
A
Abstract:
To provide shift of the immune response for reducing the occurrence of undesirable CD8+ T cell immune response specific for an antigen associated with undesirable CD8+ T cell immune response in the subject.SOLUTION: The invention provides a composition comprising: (i) a first population of synthetic nanocarriers coupled to an immunosuppressant; (ii) a second population of synthetic nanocarriers coupled to a MHC Class I-restricted and/or MHC Class II-restricted epitope of an antigen associated with undesirable CD8+ T cell immune response. The invention also provides formulations comprising the composition and methods for preparing them.SELECTED DRAWING: Figure 5

Inventors:
CHRISTOPHER FRASER
TAKASHI KEI KISHIMOTO
ROBERTO A MALDONADO
Application Number:
JP2021121468A
Publication Date:
December 02, 2021
Filing Date:
July 26, 2021
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
SELECTA BIOSCIENCES INC
International Classes:
A61K47/69; A61K31/436; A61K39/00; A61K39/35; A61P29/00; A61P37/06; A61P37/08
Domestic Patent References:
JP2010505883A2010-02-25
JP2011500569A2011-01-06
JP2010535025A2010-11-18
Other References:
BEEVERS CS, ET AL.: "Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells", INTERNATIONAL JOURNAL OF CANCER, vol. 119, no. 4, JPN6017003481, 2006, pages 757 - 764, ISSN: 0005024835
BLOOD, 2010, VOL. 116, NO. 21, PP. 1541, STN [ONLINE], RETRIEVED ON 2021.3.19, RETRIEVED FROM : BIOS, JPN6021011002, ISSN: 0005024836
BIOCHEMISTRY, vol. 38, no. 50, JPN6017047896, 1999, JP, pages 16663 - 16670, ISSN: 0005024837
Attorney, Agent or Firm:
Kiyoji Kuzuwa



 
Previous Patent: Recombinant glycosylated eculizumab and eculizumab mutants

Next Patent: Tolerant synthetic nanocarriers to reduce immune response to therapeutic proteins